Priya Kishnani
Pediatrics · Durham, NCNPI 1114001021
Payments from drug & device makers
What this record shows
The money is spread across several categories — other (54.4%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Asklepios Biopharmaceutical Inc. at 47.9% of the total. Reporting peaked in 2023 at $1,806,469 and has fallen 82.3% since, to $320,067 in 2025. Among pediatrics clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 333 payments — averaging $17,436 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Asklepios Biopharmaceutical Inc.$2.8M
- Alnylam Pharmaceuticals Inc.$2M
- Bayer$379K
- Sanofi$270K
- Amicus Therapeutics, Inc.$125K
- AstraZeneca$99K
- plus $162K from 13 others
Across 769 payments — averaging $19,066 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi$9M
- Amicus Therapeutics, Inc.$4.1M
- Sanofi US Services Inc.$536K
- AstraZeneca$494K
- Takeda Pharmaceuticals U.S.A., Inc.$266K
- Ultragenyx Pharmaceutical Inc.$231K
- plus $95K from 2 others
What the payments were for
- Consulting fees$2,457,85542%
- Speaking & faculty fees$91,6052%
- Travel & lodging$92,3412%
- Food & beverage$4,8160%
- Other$3,159,68354%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Asklepios Biopharmaceutical Inc. | 2 | $2,780,494 |
| Alnylam Pharmaceuticals Inc. | 24 | $1,990,300 |
| Bayer | 1 | $379,189 |
| Sanofi | 143 | $270,012 |
| Amicus Therapeutics, Inc. | 54 | $124,853 |
| AstraZeneca | 41 | $99,069 |
| Sanofi-aventis U.S. LLC | 19 | $72,805 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $30,541 |
| Shire North American Group Inc | 11 | $17,182 |
| Chiesi USA, Inc. | 2 | $10,695 |
| Swedish Orphan Biovitrum AB | 1 | $10,350 |
| Sanofi US Services Inc. | 1 | $6,040 |
| Regeneron | 8 | $5,868 |
| Bioverativ Therapeutics Inc. | 2 | $3,227 |
| F. Hoffmann-la Roche AG | 1 | $2,540 |
| Modernatx, Inc. | 1 | $2,320 |
| Cycle Pharmaceuticals Inc | 1 | $675 |
| Eli Lilly | 1 | $118 |
| Biomarin Pharmaceutical Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,806,301 in reported general payments places this provider in the 95th percentile of 1,818 pediatrics providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StrensiqAsfotase Alfa | 55 | $5,875,316 |
| NexviazymeAvalglucosidase Alfa-Ngpt | 23 | $1,936,845 |
| CerdelgaEliglustat Tartrate | 25 | $760,307 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaStrensiq | $99,069 | $5,875,31655 claims |
| SanofiNexviazyme, Cerdelga | $270,012 | $2,697,15348 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,818 pediatrics providers in North Carolina.
Other pediatrics in Durham
- Dwight KoeberlDurham$8.4M
- Edward SmithDurham$164K
- Daniel LandiDurham$70K
- Rasheed GbadegesinDurham$50K
- Mohamad MikatiDurham$35K
- David VanmaterDurham$32K
- Stephanie DearmeyDurham$30K
- Emmanuel WalterDurham$15K
- William MalcolmDurham$14K
- Charlene WongDurham$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.